Literature DB >> 34364387

The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis.

Hojatolla Nikravesh1,2, Mohammad Javad Khodayar2,3, Babak Behmanesh4, Masoud Mahdavinia5,6, Ali Teimoori7, Soheila Alboghobeish8, Leila Zeidooni2.   

Abstract

BACKGROUND: 5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance. The ultimate goal of cancer therapy is induction of cancer cell death to achieve an effective outcome with minimal side effects. The present work aimed to assess the anti-cancer activities of mitocans which can be considered as an effective anticancer drug due to high specificity in targeting cancer cells.
METHODS: MTT (3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay was performed to determine the effects of our mitocans on cell viability and cell death. Apoptosis and necrosis, caspase 3 activity, mitochondrial membrane potential and ROS production in HT29 cell lines were analyzed by ApopNexin™ FITC/PI Kit, Caspase- 3 Assay Kit, MitoTracker Green and DCFH-DA, respectively. Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes in HT29 cell lines.
RESULTS: Treatment with mitocans (3Br-P + DCA) inhibited the growth of HT29. Moreover, 3Br-P + DCA significantly induced apoptosis and necrosis, activation of caspase 3 activity, depolarize the mitochondrial membrane potential, and ROS production. At a molecular level, 3Br-P + DCA treatment remarkably down-regulated the expression of Bcl-2, while up-regulated the expression of Bax.
CONCLUSION: Mitocans, in particular the combined drug, 3Br-P + DCA, could be regarded and more evaluated as a safe and effective compound for CRC treatment. Targeting hexokinase and pyruvate dehydrogenase kinase enzymes may be an option to overcome 5-FU -mediated chemo-resistant in colorectal cancer.
© 2021. The Author(s).

Entities:  

Keywords:  3-Bromopyruvate; 5-fluorouracil; Apoptosis; Colorectal cancer cells; Dichloroacetate

Year:  2021        PMID: 34364387     DOI: 10.1186/s12885-021-08564-3

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  19 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.

Authors:  Jhih-Bin Chen; Ting-Rong Chern; Tzu-Tang Wei; Ching-Chow Chen; Jung-Hsin Lin; Jim-Min Fang
Journal:  J Med Chem       Date:  2013-04-22       Impact factor: 7.446

3.  Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis.

Authors:  Dianlong Chong; Linyan Ma; Fang Liu; Zhirui Zhang; Surong Zhao; Qiang Huo; Pei Zhang; Hailun Zheng; Hao Liu
Journal:  Anticancer Drugs       Date:  2017-09       Impact factor: 2.248

4.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

5.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

6.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy.

Authors:  Mi Kyung Yu; Jinho Park; Sangyong Jon
Journal:  Theranostics       Date:  2012-01-01       Impact factor: 11.556

Review 9.  Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.

Authors:  Varda Shoshan-Barmatz; Yakov Krelin; Anna Shteinfer-Kuzmine; Tasleem Arif
Journal:  Front Oncol       Date:  2017-07-31       Impact factor: 6.244

10.  Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.

Authors:  Uddin Md Nazim; Mohammad Rasheduzzaman; You-Jin Lee; Dai-Wu Seol; Sang-Youel Park
Journal:  Oncotarget       Date:  2017-03-14
View more
  1 in total

1.  3-Bromopyruvic acid regulates glucose metabolism by targeting the c-Myc/TXNIP axis and induces mitochondria-mediated apoptosis in TNBC cells.

Authors:  Jiachen Li; Jianmin Pan; Yang Liu; Xiaohui Luo; Cheng Yang; Wangfa Xiao; Qishang Li; Lihui Yang; Xiaodong Zhang
Journal:  Exp Ther Med       Date:  2022-06-16       Impact factor: 2.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.